ClinicalTrials.gg
CompletedNCT00432731Updated Mar 14, 2017

Safety Study of a Refrigerator-stable Formulation of VARIVAX®

A Phase 4 interventional study of VARIVAX® and M-M-RTM II in Varicella, Measles and Mumps, sponsored by Merck Sharp & Dohme LLC. Completed at 25 sites in 2 countries. Open to participants aged 12 Months to 15 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
12 Months to 15 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Enrollment
15th of 36
500 · median 404
Started
2004
the only one that year
Phase 4
14 of 36
2 open now
Registered
5th of 36
by date
Lead sponsor
5 of 36
Merck Sharp & Dohme LLC

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 15th largest by enrollment, is the only one that started in 2004, is one of 14 in phase 4, and was the 5th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 12 Months to 15 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

Primary objective:

To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination.

Secondary objectives: NA

03

Conditions studied

  • Varicella
  • Measles
  • Mumps
  • Rubella

Keywords

  • Prevention of : Varicella
  • Measles
  • Mumps
  • Rubella
04

Who can participate

Ages eligible
12 Months to 15 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy infants from 12 months of age to 15 months of age.
  2. Consent form signed by both parents or by the legal representative(s), properly informed about the study,
  3. Parent(s) able to understand the protocol requirements and to fill in the Diary Card.

Exclusion criteria

Exclusion Criteria:

  1. Prior receipt of measles, mumps, rubella or varicella vaccine either alone or in combination vaccine,
  2. Known or suspected clinical history of infection with measles, mumps, rubella, varicella or zoster,
  3. Any known recent (≤30 days) exposure to measles, mumps or rubella,
  4. Any known recent (≤30 days) exposure to varicella or zoster involving:
  5. Any recent (≤3 days) history of febrile illness (rectal temperature ≥38.0°C),
  6. Active untreated tuberculosis,
  7. Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems,
  8. Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,
  9. Any previous (≤150 days) receipt of immune serum globulin or any blood-derived products or scheduled to be administered through visit 3,
  10. Any recent receipt of an inactivated or a (≤ 30 days) or scheduled vaccination through visit 3
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
500 participants

Interventions

06

Study locations

25 sites
  • Amboise, France
  • Ancenis, France
  • Betton, France
  • Chateaubriant, France
  • Courbevoie, France
  • Essey les Nancy, France
  • Floirac, France
  • Fougères, France
  • Garches, France
  • Gradignan, France
  • Issy Les Moulineaux, France
  • Joué-les-Tours, France
  • Libourne, France
  • Lingolsheim, France
  • Merignac, France
  • Nancy, France
  • Paris, France
  • Rueil Malmaison, France
  • Strasbourg, France
  • Suresnes, France
  • Tours, France
  • Tresses, France
  • Vandoeuvre les Nancy, France
  • Villers les Nancy, France
  • Ragusa, Italy
07

References and documents

Publications

  • Ferrera G, Gajdos V, Thomas S, Tran C, Fiquet A. Safety of a refrigerator-stable varicella vaccine (VARIVAX) in healthy 12- to 15-month-old children: A randomized, double-blind, cross-over study. Hum Vaccin. 2009 Jul;5(7):455-60. doi: 10.4161/hv.8269. Epub 2009 Jul 23. PubMed 19305145 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2007
First posted
Feb 8, 2007
Start
Dec 2004
Primary completionActual
Sep 2005
CompletionActual
Sep 2005
Last update
Mar 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00432731
Responsible party
Sponsor
First posted
Feb 8, 2007
Start date
Dec 2004
Primary completion
Sep 2005
Completion
Sep 2005
Last update
Mar 14, 2017

Study contacts

Anne FIQUET, MD
study director · SPMSD
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion